

1 **Distinct immune signatures are a potent tool in the clinical management of**  
2 **cytokine-related syndrome during immune checkpoint therapy**

3

4 Douglas Daoudlarian<sup>1</sup>, Amandine Segot<sup>2</sup>, Sofiya Latifyan<sup>3</sup>, Robin Bartolini<sup>1</sup>, Victor Joo<sup>1</sup>,  
5 Nuria Mederos<sup>3</sup>, Hasna Bouchaab<sup>3</sup>, Rita Demicheli<sup>3</sup>, Karim Abdelhamid<sup>3</sup>, Nabila Ferahta<sup>3</sup>,  
6 Jacqueline Doms<sup>1</sup>, Grégoire Stalder<sup>2,4</sup>, Alessandra Noto<sup>1</sup>, Lucrezia Mencarelli<sup>1</sup>, Valérie  
7 Mosimann<sup>3</sup>, Dominik Berthold<sup>3</sup>, Athina Stravodimou<sup>3</sup>, Claudio Sartori<sup>5</sup>, Keyvan  
8 Shabafrouz<sup>3</sup>, John A Thompson<sup>6</sup>, Yinghong Wang<sup>7</sup>, Solange Peters<sup>3</sup>, Giuseppe Pantaleo<sup>1</sup>,  
9 Michel Obeid<sup>1\*</sup>

10

11 <sup>1</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of  
12 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne,  
13 Switzerland

14 <sup>2</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of  
15 Oncology, Service and Central Laboratory of Hematology, Rue du Bugnon 46, CH-1011  
16 Lausanne, Switzerland

17 <sup>3</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of  
18 Oncology, Medical Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

19 <sup>4</sup>Service of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-  
20 Champsec 86, CH-1951 Sion, Switzerland

21 <sup>5</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of  
22 medicine, internal medicine service, Rue du Bugnon 17, CH-1011 Lausanne, Switzerland

23 <sup>6</sup>Department of Medicine, Fred Hutchinson Cancer Research Center, University of  
24 Washington, Seattle, WA, USA

25 <sup>7</sup>Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD  
26 Anderson Cancer Center, Houston, TX, USA

27

28 **\*Corresponding author:**

29 Pr Michel Obeid, MD-PhD

30 Lausanne Center for Immuno-Oncology Toxicities LCIT

31 Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland

32 Centre Hospitalier Universitaire Vaudois (CHUV)

33 **Email:** michel.obeid@chuv.ch

34

35 **KEY WORDS:** Immune profiling, immune checkpoint inhibitors, cytokine release  
36 syndrome, sepsis, hemophagocytic lymphohistiocytosis, biomarkers, decision tree.

37

38

39

40 **Abstract**

41 Immune-related cytokine release syndrome (irCRS) frequently occurs during immune  
42 checkpoint inhibitor (ICI) therapy. In the present study, we have attempted to identify  
43 biomarkers in oncology patients experiencing irCRS-like symptoms (n=35), including 9  
44 patients with hemophagocytic lymphohistiocytosis (irHLH)-like manifestations (8 classified  
45 as Grade (G) 4 irCRS and 1 as G3 irCRS) and 8 with sepsis, differentiating between irCRS,  
46 irHLH and sepsis. Patients grouped in three clusters based on distinct cytokine profiles and  
47 survival outcomes. We identified 24 biomarkers that significantly discriminated between  
48 irHLH and irCRS G3 ( $P < 0.0455$  to  $< 0.0027$ ). Notably, HGF and ferritin demonstrated  
49 superior predictive values over the traditional HScore, with a positive predictive value (PPV)  
50 and negative predictive value (NPV) of 100%. Furthermore, CXCL9 not only distinguished  
51 between irHLH and irCRS G3, but was also a predictor of treatment intensification with  
52 tocilizumab (TCZ) with a PPV of 90% and a NPV of 100%. Other parameters, such as  
53 leukocyte count, neutrophils, ferritin, IL-6, IL-7, EGF, fibrinogen, and GM-CSF, were  
54 effective in discriminating sepsis from high-grade irCRS with a PPV of 75-80% and an NPV  
55 of 100%. In comparison to sepsis, the frequencies of CXCR5+ or CCR4+ CD8 memory,  
56 CD38+ ITM monocytes, and CD62L+ neutrophils were observed to be higher in high-Grade  
57 irCRS. Of note, TCZ treatment led to complete resolution of clinical symptoms in 12 patients  
58 with high-grade irCRS refractory to corticosteroids (CS). These findings demonstrate the  
59 power of unique immunologic biomarkers in determining the severity of irCRS, in predicting  
60 survival, and distinguishing between high-grade irCRS, irHLH and sepsis. Therefore, these  
61 distinct unique signatures are instrumental for the optimal development of personalized  
62 clinical and therapeutic management in patients experiencing irCRS patient.

63

64

65 **Main**

66 Immune Checkpoint Inhibitors (ICIs) have reshaped the anticancer landscape, showing  
67 remarkable efficacy across a spectrum of malignancies (1). However, ICIs are frequently  
68 associated with immune-related adverse events (irAEs) (2), which encompass a range of  
69 immune-mediated toxicities that raise substantial clinical challenges (1, 3). Among these,  
70 immune-related cytokine release syndrome (irCRS) is of particular concern due to its  
71 potential severity and life-threatening manifestations(4). irCRS is characterized by an acute,  
72 systemic inflammatory response, primarily mediated by an extensive release of cytokines.  
73 Historically, irCRS was associated with monoclonal antibodies (mAbs) such as rituximab,  
74 brentuximab and obinutuzumab and more recently with T-cell-engaging therapies (e.g.,  
75 bispecific T-cell-engaging (BiTE) single-chain antibodies) and chimeric antigen receptor  
76 (CAR) T cells therapies. irCRS is now increasingly observed in the context of ICI therapy (4-  
77 12). Severe irCRS can lead to multi-organ dysfunction and, in extreme cases, can be fatal  
78 (13).

79 The clinical features and laboratory alterations of irCRS itself are not specific and may  
80 overlap or coincide with infectious diseases (14). In severe cases, irCRS may present with  
81 sepsis-like clinical signs and laboratory changes mimicking sepsis, macrophage activation  
82 syndrome or immune-related hemophagocytic lymphohistiocytosis (irHLH) (15-17).  
83 Importantly, a subgroup of patients treated with CAR-T cells (18) or BITE (19) can develop  
84 HLH-like features as a severe variant of CRS. In addition, CAR T-cell associated HLH  
85 (carHLH) identified as a CRS variant presented cytokine profiles and clinical manifestations  
86 like secondary HLH/macrophage activation syndrome (MAS) (18, 20). HLH can present with  
87 a wide spectrum of manifestations ranging from isolated biological abnormalities to a severe  
88 multi-organ clinical syndrome. Distinguishing between irCRS, especially in high grade (15),  
89 and sepsis (21) in patients receiving ICI therapy is crucial for effective clinical management.

90 An important unanswered dimension in the progression of irCRS is the extent to which the  
91 hyperinflammatory response evolves into or coexists with a compensatory anti-inflammatory  
92 response syndrome (irCARS) (22-26). This balance between pro- and anti-inflammatory  
93 forces is critical to understanding whether a pronounced anti-inflammatory phase could  
94 emerge in response to the inflammatory cascade seen in irCRS. The potential transition from  
95 an overwhelming inflammatory response to a compensatory anti-inflammatory phase could  
96 have profound implications for patients' management and treatment outcomes. Furthermore,  
97 the possibility that high-grade irCRS may present with (HLH)-like manifestations adds an  
98 additional layer of complexity to the diagnosis and management of severe cases. Delineation  
99 of this continuum and its potential overlap with HLH-like presentations is essential to  
100 optimize therapeutic strategies and clinical outcomes.

101 A variety of grading systems for CRS have been proposed (27-30) with the objective of  
102 establishing standardized criteria. However, the current grading systems present several  
103 limitations and the diversity of criteria used are at the base of the inconsistency in evaluating  
104 of the safety profiles of different therapeutic agents, and the source of clinical  
105 misclassification. For instance, the performance of the HScore (31), traditionally used to  
106 estimate the individual risk of reactive HLH, may not be appropriate in the case of irHLH  
107 resulting from ICI-associated irAEs. Improving these grading systems and scores with precise  
108 immune measurements offer a promising avenue for refining the accuracy of severity grading  
109 and prognostic predictions, with the ultimate goal of rationalizing patient management and  
110 improving therapeutic outcomes.

111 In the present study, we investigated whether immunologic biomarkers can contribute to  
112 establishing solid criteria to apply to the clinical grading and classifications of ICI-associated  
113 irAEs. For these purposes, comprehensive set of 115 biomarkers, including 50 cytokines,  
114 chemokines and growth factors and 44 cellular markers were analyzed. Our ultimate

115 objective was to identify specific biomarkers that can discriminate between the different  
116 clinical manifestations of irCRS including irHLH and sepsis, and to predict severity, and  
117 patient survival. These findings are expected to facilitate the development of tailored  
118 therapeutic interventions.

119

## 120 **Clinical and demographic characteristics of the cohort.**

121 Of the 709 identified patients treated with ICI at the Lausanne University Hospital between  
122 2020 and the end of 2023, 43 patients presented with clinical and biological presentation of  
123 systemic inflammatory response syndrome (SIRS) such as sepsis or irCRS according to  
124 ACCP/SCCM Consensus Conference Committee (32, 33) (**Supplementary Table 1**). Of  
125 these, 35 patients were included in the final analysis as described in the study flowchart  
126 (**Supplementary Fig. 1**). A subset of 28 patients were diagnosed with grades 1 to 4 of irCRS  
127 according to the Lee grading scale (34) and 7 patients were diagnosed with sepsis,  
128 microbiologically documented, including 2 cases of viral and 5 of bacterial sepsis. Extensive  
129 screening to exclude an infection as the cause of CRS was part of our local standard of care  
130 for irCRS (including HLH). Among the 28 patients with irCRS, 12 [43%] were classified as  
131 low-G irCRS (G1, G2) and 16 [57%] as high-G irCRS (G3, G4). Of note, 9 out of 28 (32%)  
132 met the criteria of reactive HLH according to the criteria (31). The use of five of the eight  
133 diagnostic criteria from HLH-2004 (35) has proven to be an effective tool for the diagnosis of  
134 irHLH. Adjustments to the HLH-2004 criteria, including setting hyperferritinemia cutoffs at  
135 3000 µg/L and fever at 38.2°C, have increased sensitivity and specificity to 97.5% and  
136 96.1%, respectively, as recently reported (36). All of our irHLH cases presented with  
137 hyperferritinemia greater than 3000 µg/L, even those with an HScore as low as 162, and  
138 showed conventional biological changes such as hepatitis, renal dysfunction, cytopenia,  
139 hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis in the bone marrow and

140 spleen (although only three patients were biopsied). In addition, elevated levels of soluble  
141 CD25 (IL-2R) and key clinical features such as persistent fever and multi-organ dysfunction  
142 were observed in all cases.

143 Among the irHLH patients, 1 of the 9 patients was classified as irCRS G3 and 8 were  
144 classified as irCRS G4. None of the non-irHLH patients were classified as G4. Melanoma  
145 and lung cancer were the two most common types of cancer, with 17 out of 35 patients (49%)  
146 and 11 out of 35 patients (31%) respectively. Treatments modalities included anti-PDL-1 for  
147 3 patients (9%), anti-PD-1 for 11 (32%), anti-PD-1 and anti-CTLA4 combination for 21  
148 patients (60%) and chemo-immunotherapy for 9 patients (25.7%). The median follow-up  
149 after the first ICI administration was 29.5 months (95% CI: 13.68-44.44). Of the 28 patients  
150 with irCRS, 3 (11%) received corticosteroids (CS) alone, 13 (46%) received CS combined  
151 with tocilizumab (TCZ), and 12 (43%) did not receive any immunosuppressive treatment.  
152 Patients treated with anti-PD-1 and anti-CTLA4 combination therapy had a higher frequency  
153 of high-G (G3, G4) irCRS (75%, n=12/16) compared to those treated with anti-PD-1  
154 monotherapy (25%, n=4/16). The median time to the onset of low- and high-G irCRS was 1.3  
155 months (95% CI: 0.23-26.1) and 2.5 months (95% CI: 1.35-5.46), respectively.

156

### 157 **Comprehensive cytokine and biological profiles across different clinical grades of irCRS**

158 To characterize the inflammatory profile of irCRS, we analyzed a large panel of classical and  
159 inflammatory biomarkers in patients with different clinical grades (G1 to G4). Of the 28  
160 patients analyzed for irCRS, three were excluded from cytokine analysis due to ongoing  
161 immunosuppression at the time of samples collection. All other patients were screened for  
162 cytokines after referral to the Service of Immunology and Allergy prior to initiation of  
163 immunosuppression. Standard laboratory tests showed a significant association between  
164 irCRS severity and elevated levels of aspartate aminotransferase (AST), alanine

165 aminotransferase (ALT), alkaline phosphatase (AP), gamma-GT (GGT), and ferritin, as well  
166 as decreased levels of fibrinogen (**Fig. 1a-1c**). Notably, coagulation abnormalities escalated  
167 with irCRS severity, characterized by elevated d-dimer levels and reductions in platelets,  
168 fibrinogen, prothrombin ratio, and activated partial thromboplastin time. The coagulopathy  
169 was particularly pronounced in grade 4 (G4) patients (**Fig. 1b-1c**).

170 With regard to the analysis of the serum levels of a large panel (n=45) of  
171 cytokines/chemokines and growth factors, 14 were found to be increased as compared to  
172 baseline, i.e. prior to the initiation of ICI therapy and correlated with the irCRS grade  
173 severity. These included the chemokines CXCL9, CXCL10, CXCL13, CCL2, CCL3, CCL4,  
174 CCL5 and CCL11 (**Fig. 1d-1f**), the growth factors SCF and HGF, (**Fig. 1g**), the  
175 inflammatory cytokines IL-6, IL-18 and IFN- $\gamma$ , and the anti-inflammatory cytokines IL-1RA  
176 and IL-10. (**Fig. 1h**). Analysis of anti-inflammatory cytokines revealed an increase in IL-1RA  
177 in all irCRS grades with irCRS severity, and a significant increase in IL-10 levels in G4 (**Fig.**  
178 **1e**).

179 By analyzing the correlation matrix of biomarkers across all irCRS patients, a complex  
180 network of positive and negative correlations was revealed. CRP showed a positive  
181 correlation with ferritin, IL-18, IL-6 and ALP, but a negative correlation with Hb. Inversely,  
182 Hb showed a negative correlation with IL-6 (**Supplementary Figure 2a**). Ferritin, a key  
183 marker of inflammation, correlated with a wide array of biomarkers, including PDGF-B,  
184 CCL2, HGF, SCF, CXCL13, CXCL9, IL-18, ALT, AST, CCL3, IL-1RA, CXCL10, CRP,  
185 CXCL1, IL-10, IFN- $\gamma$ , and ALP (**Supplementary Figure 2**). Certain biomarker correlations  
186 were specific to patients with high-G and not observed in low-G such as IFN $\gamma$ /IL-1RA, IL-  
187 10/HGF, IL-10/IL-1RA, IL-10/ferritin, d-dimer/ferritin, CRP/ferritin, HGF/ferritin and  
188 ALT/Hb (**Supplementary Figure 2d-h,m,n,o**) In contrast, other biomarker pairs, including  
189 CXCL10/CXCL9, PDGF-BB/EGF and CXCL9/ferritin exhibited correlations in both low-G

190 and high-G (**Supplementary Figure 2b, c, l**). However, fibrinogen/ferritin and IL-6/Hb  
191 showed predominantly negative correlations in high-G (**Supplementary Figure 2i, p**).  
192 Therefore, these results indicated that a immunological markers are increased in patients with  
193 irCRS, they correlate with the severity of the clinical grading, and are positively or negatively  
194 correlated with conventional biological markers.

195

### 196 **Variations in immune cell subsets are associated with clinical severity of irCRS.**

197 Due to the limited sample size, we pooled mass cytometry data of patients into low-G (G1,  
198 G2) and high-G (G3, G4) for analysis. As we observed multiple differences in several  
199 immune subsets, we will only describe the most profound variations common to both low and  
200 high G irCRS (**Supplementary Figure 3, p values in Supplementary File 1**). The analysis  
201 of T-cell dynamics reveals a significant increase in several activated memory T cell subsets  
202 of CD4+ and CD8+ T cells, such as central memory (CM), transitional memory (TM), and  
203 effector memory (EM). These subsets were characterized by HLA-DR+ and CD38+  
204 expression (**Supplementary Figure 3a-3b**). Additionally, we observed an increased  
205 frequency of CD38+ monocytes in classical (CL), intermediate (ITM), and non-classical  
206 memory (NCL), and a decrease in CD141+ DC, conventional mDC, and pDC  
207 (**Supplementary Figure 3c and 3e**). Mature neutrophils decreased while immature  
208 neutrophils and all CD38+ and CD62L+ neutrophil subsets increased (**Supplementary**  
209 **Figure 3f**). Other subsets showed no significant changes (**Supplementary Figure 3d-3g**).  
210 The only major difference between high and low-G was the decreased frequency of switched  
211 memory (SM) IgA2+ B cells and CXCR3+ NCL monocytes in low-G (**Supplementary**  
212 **Figure 3**).

213



214 **Identification of clusters with different survival linked to distinct cytokine profiles by**  
215 **using classical biomarkers.**

216 It was then determined whether distinct biomarkers profiles defined different survival groups  
217 based on their biomarkers profile. We thus performed K-means unsupervised clustering and  
218 several biomarkers were considered, including those used in the HScore, alone (**Fig. 2c**),  
219 combined with CRP (**Fig. 2d, supplementary Table 4**) or creatinine (**Fig. 2e**) or both (**Fig.**  
220 **2f, Supplementary Table 4**). To determine the optimal number of clusters, K-means  
221 clustering was evaluated for 1 to 4 clusters using the silhouette method. An example of the  
222 clustering performance on the PCA dimension-reduced plot for clusters C1 to C3 (**Fig. 3a**)  
223 and the corresponding silhouette curve (**Fig. 3b**) are shown. The HScore alone did not  
224 allowed identification of clusters associated with different survival from the onset of irCRS.  
225 However, the addition of biomarkers such as CRP and creatinine improved clustering  
226 performance. Using this approach, the most insightful results were obtained when multiple  
227 biological biomarkers were combined, including CRP, ferritin, creatinine, AST, ALT, total  
228 bilirubin, PAL, GGT, leukocytes, neutrophils, and Hb (**Fig. 3**). This approach led to the  
229 identification of three distinct patient clusters in a two-steps approach (**Fig. 3a-3b and**  
230 **Supplementary Table 5**). First, a cluster of three patients (Cluster 3) with significantly lower  
231 survival from irCRS onset and a combined cluster (1+2) were identified (**Fig. 3a, 3c**). On the  
232 remaining combined cluster (1+2), optimal clustering identified two distinct clusters, Cluster  
233 1 and Cluster 2. Survival outcomes from the onset of irCRS differed significantly among the  
234 three clusters. Cluster 1 showed the most favorable prognosis, with a 100% 2-year survival  
235 rate, Cluster 2 presented an intermediate survival outcome, with 47% of patients surviving at  
236 2 years and Cluster 3 had a 0% survival rate at 6 months (**Fig. 3c**). These survival trends  
237 were further supported by distinct profiles of overall survival (OS) and survival from the  
238 initiation of ICI treatment (**Fig. 3c**). Interestingly, the three clusters showed different patterns

239 of clinical severity. Cluster 1 had a mixed composition of high-G cases, including both grade  
240 3 (G3) and grade 4 (G4) irCRS cases whereas cluster 2 was predominantly low-G with 75%  
241 of cases. Notably, cluster 3 was characterized exclusively by the presence of three patients  
242 with irHLH thus confirming being the cluster associated with the most severe clinical  
243 presentation (**Fig. 3d**). Further delineation of clusters differences through biological profiling  
244 revealed that cluster 3 was also associated with the highest degree of biological perturbations  
245 and impact on multiple organs. Significant abnormalities were observed in markers of liver  
246 (AST, ALP) and kidney (creatinine) functions, of inflammatory markers (CRP, ferritin,  
247 lymphopenia), of coagulation (prothrombin ratio, activated partial thromboplastin time, d-  
248 dimer), and hematology (anemia) (**Fig. 3e-3h**).

249 Additional characterization through immune profiling revealed that Cluster 3 was  
250 characterized by a highly inflammatory profile with elevated levels of various cytokines (IL1-  
251 RA, IL-6, IL-10, IL-18, IFN- $\gamma$ ), chemokines (CCL2, CXCL8, CXCL9, CXCL10, CXCL12,  
252 CXCL13), and growth factors (HGF, SCF) (**Fig 3i-3k**). This inflammatory profile indicates a  
253 robust reactive inflammatory response, likely contributing to the clinical severity observed in  
254 Cluster 3. To assess the individual weight of different biomarkers on survival after the onset  
255 of irCRS, a 1D K-means clustering technique was applied to all measured cytokines and  
256 biological biomarkers, followed by univariate Cox proportional hazards modeling. As shown  
257 in **Supplementary figure 4a-4b**, this methodological approach facilitated the identification  
258 of high and low clusters for each biomarker, including creatinine, hemoglobin, and  
259 prothrombin ratio. Analysis revealed that clusters characterized by high creatinine, low  
260 hemoglobin, or low prothrombin ratio were significantly correlated with reduced survival  
261 after irCRS onset. The results showed a hazard ratio (HR) of 5.605 ( $p=0.0068$ ) for the high  
262 creatinine cluster, an HR of 6.643 ( $p=0.015$ ) for the low hemoglobin cluster, and an HR of  
263 5.811 ( $p=0.0324$ ) for the low prothrombin ratio cluster (**Supplementary Figure 4a**). These

264 findings were further supported by distinct Kaplan-Meier survival curves, showing the  
265 negative impact of these biomarker levels on patient outcomes post-irCRS onset  
266 (**Supplementary Figure 4c-4e**). Interestingly, when dual biomarkers such as hemoglobin and  
267 creatinine were combined for survival prediction, the accuracy was significantly improved.  
268 However, the predictive value reached its peak - 100% accuracy - when hemoglobin,  
269 creatinine and prothrombin ratio were integrated into a unified clustering model  
270 (**Supplementary Figure 4f-4g**). This improvement in prognostic prediction by a multi-  
271 biomarker approach highlights the substantial benefits of including a combination of  
272 biological markers to assess survival outcomes in irCRS patients.

273

#### 274 **Biomarker performance in differentiating irCRS Grade 3 from irHLH and predicting** 275 **clinical severity and tocilizumab therapy escalation.**

276 As mentioned above, the primary objective was to identify biomarkers to improve diagnostic  
277 accuracy, the evaluation of clinical severity and to predict treatment intensification in patients  
278 with irCRS and irHLH. 45 serum biomarkers were evaluated including cytokines and  
279 biological markers in addition to those present in the traditional HScore(31). Our results  
280 confirmed the significant limitations of the HScore in the assessment of severe irCRS in  
281 patients with high-G irCRS. In fact, certain patients, despite low HScore, required escalating  
282 treatment with tocilizumab (TCZ), as observed in patients 2, 7, 9, and 11 (**Supplementary**  
283 **Figure 5a**). In irHLH patients, an HScore above 154 achieved 100% diagnostic sensitivity,  
284 identifying 2 patients with low HScore HLH probability (41% and 61%) (31) (**Fig. 4a**). In  
285 addition, a strong correlation was found between higher ferritin levels and increased clinical  
286 severity in patients with irHLH (**Fig. 4b**), with median ferritin levels > 148000 in the irHLH  
287 group well above the established highest HScore cutoff of 6000 (**Fig. 4c**). These results  
288 highlight the limitations of the traditional ferritin threshold of 6000 of the HScore (31) in this

289 context, which adds only 50 points and thus fails to capture the full extent of the  
290 inflammatory state associated with irHLH, where ferritin could rise to much higher levels.

291

292 Based on these limitations, we attempted to identify the most reliable predictive biomarkers  
293 differentiating between irHLH and irCRS G3. As detailed in the demographics, all the irCRS  
294 G4 were irHLH. Of the irCRS G3, one patient was irHLH but was excluded from the  
295 biomarker analysis because the biomarker panel was performed after initiation of  
296 immunosuppressive treatment. We analyzed 45 biomarkers including, 27 cytokines, 18  
297 biological markers including those of the HScore. We determined the cutoff values, area  
298 under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive and  
299 negative predictive values, and accuracy. This analysis identified a panel of 24 biomarkers  
300 with P-values below 0.05, ranging from <0.0455 to <0.0027 (HGF, ferritin, SCF, IL-10, IL-  
301 18, CCL4, aPTT, IL-1RA, CCL2, D-dimer, PDGF-BB, CXCL8, prothrombin time ratio,  
302 CXCL9, CCL11, LIF, ASAT, CXCL10, fibrinogen, CCL3, IL-6, CXCL13, IFN- $\gamma$  and  
303 platelets) that significantly discriminated between irHLH and irCRS G3 (**Fig 4d**). Among  
304 them, HGF, ferritin, IL-1RA, prothrombin time ratio, CXCL9 and fibrinogen showed the  
305 highest sensitivity (100%) with specificity ranging from 66% to 100%. Remarkably, HGF  
306 and ferritin showed excellent 100% accuracy whereas the sensitivity that of the HScore was  
307 only 71.43% (**Fig 4d**). Importantly, only CXCL9 and total bilirubin were significantly  
308 predictive of treatment intensification with TCZ, with sensitivities of 75 (CXCL9) to 100%  
309 (bilirubin) and specificities of 77.78% (bilirubin) to 100% (CXCL9) whereas the specificity  
310 of HScore was 66.67% (**Fig 4e**). Regarding hemodynamic instability requiring fluid  
311 resuscitation, HGF, SCF and aPTT were the best predictors with 100% accuracy, whereas the  
312 accuracy of the HScore was only 76.92% (**Supplementary Figure 5b**). For respiratory  
313 distress, CCL2, ferritin, D-dimer and aPTT were the only markers with 100% positive

314 predictive value and sensitivity, with specificity ranging between 71.43-85.71%, whereas the  
315 HScore had 83.3% accuracy and 85.71% positive predictive value (**Supplementary Figure**  
316 **5c**).

317

### 318 **High-grade irCRS and sepsis patients exhibit distinct biomarker profiles.**

319 Although patients with high-G irCRS and sepsis may present with similar clinical  
320 manifestations, it is crucial to differentiate between these two conditions. For these purposes,  
321 we compared the biomarker levels of patients with irCRS G3 or irHLH to those of patients  
322 with sepsis and identified a cytokine and immune cell signature that distinguished them. The  
323 patients with irHLH had significantly higher levels of IL-10 and IL-1RA (**Supplementary**  
324 **Figure 6a and 6d**). sCD25 was not significantly different between groups ( $p=0.08$ ), but IL-6  
325 was highest in sepsis compared to irCRS G3 (**Supplementary Figure 6a, 6d**). IFN- $\gamma$   
326 pathway was observed in irHLH, as indicated by significant increases in IFN- $\gamma$ , CXCL-9,  
327 CXCL-10 and IL-18, as well as CCL3 and CCL4, compared to sepsis and irCRS G3  
328 (**Supplementary Figure 6a and 6b**). IL-7 was significantly increased in sepsis  
329 (**Supplementary Figure 6a**). HGF was higher in irHLH compared to sepsis and irCRS G3,  
330 whereas EGF and GM-CSF were higher in sepsis compared to irCRS G3 (**Supplementary**  
331 **Figure 6c**). SCF and LIF were higher in irHLH compared to irCRS G3 (**Supplementary**  
332 **Figure 6d**). Leukocytes and neutrophils were higher in sepsis compared to irHLH and irCRS  
333 G3 (**Supplementary Figure 6e**). Ferritin, D-dimer, and transaminases were more elevated in  
334 irHLH than in sepsis and irCRS G3 (**Supplementary Figure 6f**). Furthermore, irHLH  
335 showed more severe coagulopathies, including prothrombin ratio and fibrinogen levels  
336 (**Supplementary Figure 6g**). Mass cytometry analysis between high-grade irCRS (irHLH  
337 and G3) and sepsis (**Supplementary Figure 7, p values in Supplementary File 2**),  
338 identified CD38<sup>+</sup> HLA-DR<sup>+</sup> double-positive T cells as increased in the CM, EM, and TM

339 subsets. Compared to sepsis, there was a significant increasing trend of CD4 memory CD38+,  
340 CD4 TM HLA-DR+/CD38+, CD8 memory CCR4+, and a decrease in CD8 memory  
341 CXCR5+ in high-grade irCRS. (**Supplementary Figure 7a and 7b**). Compared to sepsis,  
342 there was a significant increase in the frequency of CD38+ monocytes in the ITM subset.  
343 Additionally, there was a significant increasing trend in CL monocytes CD11c+ and CL  
344 monocytes CD38+ and in the frequency of CD16 NK cell (**Supplementary Figure 7d-7e**).  
345 Compared to sepsis, high-G irCRS exhibited decreased total neutrophils but increased  
346 CD62L neutrophils in both immature and mature subsets (**Supplementary Figure 7f**). No  
347 significant differences were observed in the other subsets (**Supplementary Figure 7d, 7e**  
348 **and 7g**).

349

350

### 351 **Discriminating irCRS Grade 3, irHLH, and sepsis through circulating biomarkers**

352 The potential of all biomarkers to discriminate between irCRS grade 3, irHLH and sepsis at  
353 the time of diagnosis was evaluated. Multiple supervised approaches were used to evaluate  
354 this. In the first approach, we analyzed 46 biomarkers including 27 cytokines, and 18  
355 biological markers. We determined cutoff values, area under the receiver operating  
356 characteristic curve (AUC), sensitivity, specificity, positive and negative predictive values,  
357 and Youden's J index for each biomarker. This analysis identified a panel of 11 biomarkers  
358 (leucocyte count, IL-7, fibrinogen, EGF, CXCL10, neutrophils, GM-CSF, ALAT, ALP, GGT  
359 and IL-6) that significantly discriminated between sepsis and irCRS high-G with P-values  
360 ranging from <0.0046 to <0.0415 (**Fig. 5a**). Among the biomarkers tested, leukocyte count,  
361 IL-7, fibrinogen, EGF, CXCL10, and neutrophils demonstrated the highest sensitivity (100%)  
362 with an excellent specificity of 92.31% (**Fig. 5a**). In addition, a panel of 10 biomarkers  
363 (leucocyte count, neutrophils, IL-6, EGF, ALP, IL-7, GM-CSF, fibrinogen, IL-15 and

364 CXCL10) was identified and significantly discriminated between sepsis and irCRS G3 with  
365 P-values ranging from  $<0.0082$  to  $<0.0472$  (**Fig. 5b**). Among the measured parameters,  
366 leukocyte count, neutrophils, IL-6, and EGF exhibited an accuracy of 100% (**Fig. 5b**). In  
367 addition, the ferritin cut-off of 23221 ng/ml was discriminating between irHLH and the rest  
368 of patients (sepsis and irCRS G3) with sensitivity and specificity of 100 % (ROC p value of  
369 0.0009) (**Fig. 5c and Supplementary Table 6**). Two additional supervised approaches were  
370 used. First using sPLS-DA (Sparse Partial Least Squares Discriminant Analysis), we found  
371 that the biomarker profiles could effectively separate the three conditions, with only one  
372 irCRS case falling between the irCRS and Sepsis clusters (**Supplementary Figure 8a**).  
373 sPLS-DA first component identified 5 biomarkers with absolute importance higher than 0.3:  
374 IL-10, HGF, IL-18, IL-1RA, and SCF (**Supplementary Figure 8b**). Component 2 identified  
375 three variables exceeding 0.3: leukocytes count, IL-7, and EGF (**Supplementary Figure 8c**).  
376 Component 1 explained most of the X axis variation notably the separation of irHLH patients  
377 identifying biomarkers previously found using the ROC curve approach (*i.e* IL-10, HGF) and  
378 component 2 the Y axis separating the sepsis from the irHLH identifying also biomarkers  
379 identified in Figure 5 (*i.e* leukocytes count, IL-7, EGF). The potential for developing a  
380 decision tree construction was explored using the random forest algorithm to identify the  
381 most predictive biomarkers for classification. Ferritin emerged as the most abundant initial  
382 node in the decision trees, with ferritin, HGF, and leukocyte count ranking as the top three  
383 biomarkers based on their average Gini coefficient across 100 trees (**Supplementary Figure**  
384 **8d and 8e**).

385 Our aim was to develop a decision tree capable of distinguishing the three CRS-like  
386 presentations within our cohort. Using ferritin with a threshold of  $>23111$  ug/L, 100%  
387 accuracy was achieved in discriminating irHLH patients from those with irCRS G3 or sepsis.  
388 Eight additional markers (CCL4, HGF, IL-1RA, IL-10, IL-18, fibrinogen, CXCL9 and



389 aPTT) have higher than 90% accuracy to identify irHLH patients from irCRS-G or sepsis  
390 (**Supplementary Table 6**). The differentiation between irCRS G3 and sepsis was further  
391 refined using three biomarkers-EGF, IL-6, and leukocytes-with specific thresholds, EGF  
392 (>51.3 pg/mL), IL-6 (>129.6 pg/mL), and leukocytes (>8.5 G/L), that allowed perfect  
393 separation between these conditions. The integration of these biomarkers facilitated the  
394 prediction of irHLH, irCRS G3, and sepsis with 100% accuracy within our cohort (**Figure**  
395 **5d**). Neutrophils count also have a 100% accuracy (**Figure 5b**) but was not included in the  
396 tree due to the lack of measurement in 1 sepsis patients. This multifaceted biomarker analysis  
397 underscores the effectiveness of integrating multiple immune profiling techniques to  
398 precisely distinguish between irCRS, irHLH and sepsis, which is critical for guiding  
399 appropriate therapeutic interventions in these clinically challenging scenarios.

#### 400 **Tocilizumab is effective treatment of corticosteroid refractory high-grade irCRS.**

401 Twelve patients with severe high-G irCRS received adjunctive therapy with TCZ, an anti-IL-  
402 6R antagonist, due to a suboptimal initial response to corticosteroids. TCZ use in  
403 irCRS/irHLH patients adheres to our standard care in combination where it is employed as a  
404 second-line escalation therapy in corticosteroid-sparing strategies, or as an initial  
405 combination therapy with corticosteroids in severe CRS cases. This in accordance to our  
406 previous work (15) which contributed to our involvement in developing the irHLH ESMO  
407 guidelines(1). These patients' data were retrospectively collected, and out of these 12  
408 patients, 3 were not included in the rest of the manuscript as their cytokines were only  
409 collected after TCZ initiation. Encouragingly, a 100% response rate to treatment with TCZ  
410 was observed, resulting in rapid and substantial clinical improvements. Importantly, all cases  
411 of irHLH were resolved and no irCRS-related mortality was observed at either 7 or 30 day  
412 (**Supplementary Table 2**). Longitudinal cytokine follow-up data were available for only 6  
413 out of 12 patients. In this subgroup, standard markers of inflammation such as cytolysis,



414 ferritin levels, C-reactive protein (CRP) and leukopenia showed significant reductions and  
415 normalization (**Fig. 6a**). Similarly, TCZ treatment induced significant reductions in all  
416 immunological markers including IFN- $\gamma$ , soluble CD25 (sCD25), IL-6, IL-18, CXCL9,  
417 CXCL10, CCL2, CCL4, CCL5, HGF, SCF, IL-10 and IL-1RA (**Fig. 6b**). Importantly, TCZ  
418 therapy did not result in any significant adverse events.

419

420

421

## 422 **Figures legend**

423 **Figure 1. Comprehensive cytokine and biological profiles for different clinical grades of**  
424 **irCRS. (a-c)**, Evaluation of serum biomarkers in patients (n=28) at the time of irCRS  
425 compared to the pre-ICI serum levels in 194 cancer patients used as reference group. (d-g)  
426 Serum levels of chemokines, growth factors and cytokines in 25 patients with different  
427 clinical grades at irCRS diagnosis compared to the pre-ICI serum levels in 194 cancer  
428 patients used as reference group. Student T test tests were used to analyze the data for  
429 statistical significance between groups, irCRS G1 were not compared to other clusters due to  
430 the low number of patients (n=2). Plots represent values with individual data points, bar  
431 represent the mean and error bars represent standard deviation. The results showed a  
432 significant difference between the groups with a P-value of less than 0.001 (\*\*P<0.001) and  
433 less than 0.0001 (\*\*\*\*P<0.0001).

434

435 **Figure 2. Exploration of 4 distinct clusterings across HScore and other biological**  
436 **parameters reveals variable strengths regarding survival from irAE.** Biological  
437 parameters were collected from irCRS patients at the time of diagnosis (n=28). (a) clustering  
438 plot for the three identified clusters based on HScore parameters. (b) silhouette plot showing  
439 the optimal number of clusters based on HScore parameters. (c) Kaplan-Meier (KM) plot  
440 showing the survival rate from irCRS onset for the three Clusters (C1, C2, C3) obtained using  
441 HScore parameters. (d) KM plot showing the survival rate from irCRS onset for the four  
442 Clusters (D1, D2, D3, D4) obtained using a combination of HScore parameters and CRP. (e)  
443 KM plot showing the survival rate from irCRS onset for the three Clusters (E1, E2, E3)  
444 obtained for the four Cluster (F1, F2, F3, F4) using a combination of HScore parameters and  
445 creatinine. (f) KM plot showing the survival rate from irCRS onset using a combination of  
446 HScore parameters, creatinine, and CRP. Log-rank tests were used to analyze the data for

447 statistical significance between groups and to calculate confidence intervals (CI) and hazard  
448 ratios (HR).

449 **Figure 3. Integration of additional circulating biomarkers enhances clustering linked to**

450 **distinct overall survival and cytokine profiles.** The biomarkers used for this other

451 clustering are CRP, ferritin, creatinine, AST, ALT, total bilirubin, ALP, GGT, leukocytes,

452 PNN and Hb collected from irCRS patients at the time of diagnosis (n=28). **(a)** Clustering

453 plot initially identified two distinct clusters: combined Cluster 1+2, and Cluster 3. **(b)** After

454 isolating the three patients belonging to cluster 3, K means clustering was applied to the

455 remaining cohort, resulting in the separation of the combined Cluster (1+2 ) into two new

456 distinct clusters, labeled as Cluster 1 and Cluster 2 **(c)** Kaplan-Meier plot showing the

457 survival rate for the three identified clusters, Cluster 1 (n=7), Cluster 2 (n=18) and Cluster 3

458 (n=3), the survival from irCRS onset, the overall survival (OS) or the survival from ICI

459 initiation. **(d)** distribution of the irCRS according to the clinical grade in each cluster. **(e-h)**

460 comparison of levels of circulating blood cells and serum biomarkers, including liver and

461 kidney functions, coagulation and inflammation parameters in each cluster. **(i-k)** comparison

462 of serum cytokine, chemokine, and growth factor levels among the three clusters. Log-rank or

463 Mantel-Haenszel (if a cluster had 0 deaths during the interval) was used to calculate CI, HR,

464 and p values for the KM curves. Student T tests were used to analyze the data for statistical

465 significance of biomarkers levels between groups. Panels E to K plots represent values with

466 individual data points, bar represent the mean and error bars represent standard deviation. CI,

467 Confidence Interval; HR, Hazard Ratio, CRP: C-reactive protein; Hb: hemoglobin; PNN:

468 polynuclear neutrophils; AST: aspartate aminotransferase; ALT: alanine transaminase; ALP:

469 alkaline phosphatase; GGT: gamma glutamyl transferase.

470

471 **Figure 4. Superior performance of HGF and ferritin in discriminating between irCRS**  
472 **G3 and irHLH, with CXCL9 and total bilirubin predicting tocilizumab therapy**  
473 **escalation.** (a) Comparison between the real diagnosis of high-G irCRS and estimation of  
474 diagnosis based to the conventional HScore. (b) Linear regression and correlation coefficient  
475 between ferritin and HScore in patients with irCRS G3 (n=7) or irHLH (n=6). (c) Median  
476 ferritin (pg/mL) in patients with irCRS G3 (n = 7) or irHLH (n = 6). (d) performance (area  
477 under the receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and  
478 negative predictive values) of each marker to discriminate irHLH (n=6) from irCRS G3  
479 (n=7). (e) Performance (area under the receiver operating curve (AUC), cut-off value,  
480 sensitivity, specificity, positive and negative predictive values) of each marker in the  
481 prediction of treatment intensification with TCZ in patients with high-G irCRS (n=13).  
482 Confidence intervals for specificity and sensitivity have been calculated using Wilson-Brown  
483 method. Panel c plot represent values with individual data points, bar represent the mean and  
484 error bars represent standard deviation.

485

486 **Figure 5. Distinct biomarker profiles in irCRS G3, irHLH and sepsis allow differential**  
487 **diagnosis.** (a) Performance (area under the receiver operating curve (AUC), cut-off value,  
488 sensitivity, specificity, positive and negative predictive values) of each marker to  
489 discriminate sepsis (n=4) from high-G irCRS (n=13). (b) Performance of each marker to  
490 discriminate sepsis (n=4) from irCRS G3 (n=7). (c) ferritin levels in patients with irHLH  
491 (n=6) vs irCRS G3 and sepsis (n=4) with area under the receiver operating curve (AUC), cut-  
492 off value, sensitivity, specificity. (d) Decision tree analysis showing the performance of each  
493 biomarker in discriminating between irCRS G3, irHLH and sepsis. Confidence intervals for  
494 specificity and sensitivity have been calculated using Wilson-Brown method. Of note,  
495 neutrophil count, alkaline phosphatase, and gamma-GT were only performed in 3 sepsis

496 patients because one patient had missing measurements at the time of inclusion. Panel c plot  
497 represent values with individual data points, bar represent the mean and error bars represent  
498 standard deviation.

499

500 **Figure 6. Longitudinal biomarker changes and biological resolution in CS-Refractory**  
501 **High-G irCRS patients treated with tocilizumab.** (a) Evolution of serum biomarker levels  
502 including AST (U/L), CRP (mg/L), ferritin ( $\mu\text{g/L}$ ), leukocytes (G/L), and (b) serum  
503 cytokine, chemokine, and growth factor levels, in patients with repeated cytokines  
504 measurements receiving tocilizumab treatment for CS-refractory high-grade irCRS (n=6).  
505 The gray boxes in panel a indicate the global period of tocilizumab treatment, while the  
506 arrows in panel b indicate individual days of tocilizumab administration.

507

508 **Supplementary Figure 1: Study flowchart**

509

510 **Supplementary Figure 2: Correlation between cytokine and biological biomarkers by**  
511 **clinical grade of irCRS.** (a) Spearman Correlation Matrix. Correlation map plotted using  
512 significance levels for the Spearman test performed with relevant serum biomarker data from  
513 all irCRS patients studied across all grades. Positive correlations are shown in shaded blue  
514 and negative correlations are shown in shaded red. Correlations with a p-value  $\geq 0.05$  are not  
515 considered significant and are left blank. Color intensities are proportional to the correlation  
516 coefficients. On the right side of the correlogram, the color legend shows the correlation  
517 coefficients and corresponding colors. (b-q) Correlation and linear regression between the  
518 level of various serum biomarkers including cytokines and biological parameters according to  
519 the clinical severity, low-grade (G1, G2) (n=12) in orange versus high-grade (G3, G4) (n=16)

520 in blue. Each point represents a unique patient time point at irCRS diagnosis. Spearman's  
521 rank correlation coefficient and significance are shown.

522

523 **Supplementary Figure 3: Comprehensive profiling of circulating immune cell**  
524 **phenotypes differentiates high from low irCRS grades. (a-g)** Heatmap showing fold  
525 change relative to pre-ICI baseline of cancer patients (n=103) of the different immune cell  
526 subsets in patients at the time diagnosis of low-G irCRS (n=10) vs high-G irCRS (n=10). **(a)**  
527 CD4 T cell subsets, **(b)** CD8 T cell subsets, **(c-e)** monocyte subsets, **(f)** NK cells, NKT cells  
528 and TCR $\gamma\delta$  T cells, **(g)** dendritic cells DCs, **(h)** neutrophils, **(i)** B cells. Values represent % of  
529 parent population as indicated in the gating strategy (Supplementary\_OLD Figure 2).  
530 Statistical significance was analyzed using Student T test between groups. \*\*\*P<0.001,  
531 \*\*\*\*P<0. EM: effector memory, CM: central memory, DC: dendritic cells, TEMRA:  
532 terminally differentiated effector memory cells re-expressing CD45RA, classical monocytes  
533 CL, intermediate monocytes ITM, and non-classical monocytes NCL

534

535 **Supplementary Figure 4: 1d K-Means clustering of biological parameters reveals high**  
536 **and low clusters with differential impact on survival from irAEs. (a)** Univariate Cox  
537 regression models for OS with the different high and low clusters identified by K-means  
538 clustering for various biomarkers (n=28). **(b)** Biomarkers levels in the different identified low  
539 and high clusters. **(c)** Kaplan-Meier curves illustrating the survival from irCRS onset in low  
540 (n=4) and high (n=23) creatinine clusters. **(d)** Survival in low (n=14) and high (n=14)  
541 hemoglobin clusters. **(e)** Survival in low (n=2) and high (n=26) prothrombin ratio clusters. **(f)**  
542 Kaplan-Meier plot showing the survival rate for the three Clusters, Cluster eF1 (n=4), Cluster  
543 eF2 (n=14) and Cluster eF3 (n=10), identified with K-means using hemoglobin (Hb) and  
544 creatinine, **(g)** Kaplan-Meier plot showing the survival rate for the four clusters, Cluster eG1

545 (n=4), Cluster eG2 (n=14), Cluster eG3 (n=6) and Cluster eG4 (n=4) identified with K-means  
546 using creatinine, Hb and Prothrombin ratio. Log-rank (Mantel-Cox) test was used to identify  
547 significant differences between groups in panels F and g, logrank for comparing two clusters  
548 in c to e.

549

550 **Supplementary Figure 5: Biomarker efficacy in the prediction of hemodynamic**  
551 **instability and respiratory distress in patients with high-G irCRS. (a)** clinical and  
552 treatment characteristics of all patients with high-G irCRS (n=13). **(b)** Performance (area  
553 under the receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and  
554 negative predictive values) of each marker in the prediction of hemodynamic instability  
555 requiring vasopressor in patients with high-G irCRS (n=7). **(c)** performance (area under the  
556 receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and negative  
557 predictive values) of each marker in the prediction of respiratory distress in patients with  
558 high-G irCRS (n=13). Confidence intervals for specificity and sensitivity have been  
559 calculated using Wilson-Brown method. TCZ: tocilizumab

560

561 **Supplementary Figure 6: Cytokine and Biological profiles for irCRS G3, irHLH and**  
562 **Sepsis. (a-d)** comparison of serum cytokine, chemokine, and growth factor levels. **(e-g)**  
563 circulating blood cells and serum biomarker levels (including liver and kidney functions,  
564 coagulation and inflammation parameters) in the three groups of patients: irCRS G3 (n=7),  
565 irHLH (n=6) and sepsis (n=4). Panels A to G plots represent values with individual data  
566 points, bar represent the mean and error bars represent standard deviation. Statistical  
567 significance was analyzed using Mann-Whitney test between groups. \*\*\*P<0.001,  
568 \*\*\*\*P<0.0001.

569

570 **Supplementary Figure 7: Comparative distribution of circulating immune cell**  
571 **populations in patients with irCRS G3, irHLH or sepsis. (a-g)** Heatmap showing fold  
572 change relative to pre-ICI baseline of cancer patients (n=103) of the different immune cell  
573 subsets in patients with irCRS G3 (n=4), irHLH (n=6) or sepsis (n=5). **(a)** CD4 T cell subsets,  
574 **(b)** CD8 T cell subsets, **(c-e)** monocyte subsets, **(f)** NK cells, NKT cells and TCR $\gamma\delta$  T cells,  
575 **(g)** dendritic cells DCs, **(h)** neutrophils, **(i)** B cells. Values represent % of parent population  
576 as indicated in the gating strategy (Supplementary\_OLD Figure 2). Statistical significance  
577 was analyzed Student T tests between groups. \*\*\*P<0.001, \*\*\*\*P<0.0001. EM: effector  
578 memory, CM: central memory, DC: dendritic cells, TEMRA: terminally differentiated  
579 effector memory cells re-expressing CD45RA, classical monocytes CL, intermediate  
580 monocytes ITM, and non-classical monocytes NCL

581

582 **Supplementary Figure 8: Clustering of circulating biomarkers provides distinction**  
583 **between irCRS, irHLH and sepsis. (a)** Supervised learning sPLS-DA approach used to  
584 separate the three subgroups: irCRS G3, irHLH and sepsis. **(b)** The variables of component 1  
585 allow for the separation of irHLH from the other 2 groups. **(c)** The variables of component 2  
586 allow the separation of irCRS grade 3 from sepsis. **(d)** random forest averaged Gini  
587 coefficient across 100 forest for all biomarkers. **(e)** Percentage as the main node of trees for  
588 all biomarkers. sPLS-DA: sparse partial least squares discriminant analysis.

589

590 **Supplementary Figure 9: Gating strategy for mass cytometry. Complete gating strategy**  
591 identify the main population with the list of antibodies and coupled antibodies.

592



593 **Supplementary Table 1: Patients, treatments, and clinical characteristics.** The principal  
594 clinical, demographic, and therapeutic data for the entire cohort (n=35) are presented in detail  
595 in this table.

596

597 **Supplementary Table 2:** clinical characteristics of irCRS patients receiving Tocilizumab  
598 treatment (n=12).

599

600

601 **Supplementary Table 3: Global biomarker table.** Summary table with for irCRS G1-G4,  
602 Bacterial sepsis, Viral sepsis, Immunosuppressed patients: N, Mean, Min, Max, Percentiles  
603 (25th,50th,75th) and SD. Lower limit of detection is included in the table for all biomarkers.

604

605 **Supplementary Table 4:** HR and P values associated with Figure 2 panels D and F. logrank  
606 test for comparing clusters in Figure 2 panels D and F

607

608 **Supplementary Table 5:** Clinical characteristics of irCRS patients within clusters identified  
609 in Figure 3

610

611 **Supplementary Table 6:** ROC curve analysis of predictors of irHLH versus irCRS-  
612 G3/Sepsis patients. ROC, AUC and p values, cutoff, Sensitivity, Specificity, Accuracy,  
613 Positive predictive value and Negative predictive value

614

615 **Supplementary File 1:** P values for comparison of mass cytometry data comparing either  
616 Low grade or high-grade patients with baseline. Statistical significance tested with Mann-  
617 Whitney test.

618

619 **Supplementary File 2:** P values for comparison of mass cytometry data comparing either  
620 high grade or sepsis patients with baseline. Statistical significance tested with Mann-Whitney  
621 test.

622

623

## 624 **Material and Methods**

### 625 **Sample collection and ethic approval**

626 All patients either signed informed consent offered to all patients to allow research use of  
627 their data in a coded fashion (called “*consentement general*”) or did not express opposition  
628 and were included thanks to article 34 of the Swiss federal law relative to human research.  
629 Research protocol was approved by the cantonal ethical committee “*Commission cantonal*  
630 *d’éthique de la recherche sur l’être humain (CER-VD)*”. All samples were harvested during  
631 the normal clinical practice, and no specific intervention on patients were performed  
632 regarding this study.

633

### 634 **Immune profiling of circulating blood immune cells population by mass cytometry**

635 Patient blood was stained as previously described (37). Briefly, cells were incubated for 30  
636 min at room temperature (RT) with a 50µL antibody cocktail of metal-conjugated antibodies.  
637 Cells were then washed and fixed with 2.4% PFA for 10 min at RT, lysed for 15 min at RT  
638 using Bulklysis solution (Cytognos), and incubated 30 min at RT with metal-conjugated  
639 antibodies. Complete list of metal-conjugated antibodies and gating strategy can be found as  
640 **Supplementary Figure 9**. Cells were washed and total cells were identified by DNA  
641 intercalation (1µM Cell-ID Intercalator, Standard BioTools) in 1.6% PFA at 4 °C overnight.

642 Labeled samples were acquired using the HELIOS CyTOF system (Standard BioTools) and  
643 FCS files were normalized to EQ Four Element Calibration Beads using the CyTOF software.

644

#### 645 **Immune profiling of serum biomarkers**

646 As previously described (38) serum concentrations of cytokines, soluble CD25, chemokines,  
647 and growth factors were determined by Luminex ProcartaPlex immunoassays for each  
648 marker. List of biomarkers, lower limit of detection and distribution of values within our  
649 cohort can be found in **Supplementary Table 3**. Samples values below or equal to the LLOD  
650 were replaced by the LLOD.

#### 651 **Statistical analysis**

652 All statistical analysis in figures comparing cytokines were performed using GraphPad Prism  
653 10.1.2. Most graphs were also done using GraphPad Prism, in exception of correlation  
654 figures, and machine learning figures that were done using R. Mass cytometry analysis was  
655 performed using FlowJo. 1-d k-mean clusters were down using the ckmeans.1.dp R packages  
656 (Song and Zhong, 2020) and optimal number of cluster evaluated using silhouette method.  
657 sPLS-DA was performed using the “mixOmics” package and random forest using the R  
658 package “randomForest”). Statistical analysis between groups have been done using either  
659 student T test, Mann-Whitney U test or 1-way ANOVA as indicated in figures. All p values  
660 below 0.05 were defined as significant.

#### 661 **Custom code availability**

662 All custom code used for analysis was written using R or Matlab R2023b. Custom code  
663 example is available on the LCIT github repository ([https://github.com/LCIT-](https://github.com/LCIT-CHUV/ImmunoTox)  
664 [CHUV/ImmunoTox](https://github.com/LCIT-CHUV/ImmunoTox)).

#### 665 **Data Availability**

666 The datasets supporting the results of this study are not publicly available. Requests for  
667 access to the dataset will be granted upon reasonable request to the principal investigator.  
668 Study data will be managed, stored, shared, and archived according to CHUV standard  
669 operating procedures to ensure the continued quality, integrity, and utility of the data.  
670  
671

## 672 **Discussion**

673 Our comprehensive study examines the immune dynamics of immune-related cytokine  
674 release syndrome (irCRS) and reveals distinct patterns across CRS grades. We found that  
675 CXCL9, CXCL10 and IFN- $\gamma$  levels increase with CRS severity, suggesting their role as early  
676 markers of irCRS onset and progression. This finding underscores the importance of  
677 monitoring these markers for early intervention, potentially reducing the severity of irCRS  
678 and improving outcomes. When comparing irHLH patients to those with grade 3 irCRS, we  
679 found significant elevations in proinflammatory and antitumor cytokines (including IFN- $\gamma$ ,  
680 IL-6, IL-18, CXCL9, CXCL10, CXCL13, CCL2, CCL3, CCL4, HGF, SCF, and PDGF-B),  
681 along with increases in anti-inflammatory cytokines (IL1-RA, IL-10). This cytokine profile  
682 suggests a complex inflammatory continuum at the intersection of irCRS severity, irCARS,  
683 and oncologic response, highlighting the nuanced immune responses induced by ICI therapy.  
684 Our study reveals the simultaneous emergence of irCARS and irCRS during ICI treatment,  
685 characterized by increased anti-inflammatory cytokines, particularly IL1-RA and IL-10. This  
686 observation highlights a dynamic balance between pro-inflammatory and anti-inflammatory  
687 responses that intensifies as CRS progresses. Specifically, we observed a significant increase  
688 in IL-10 at grade 4, suggesting its role in amplifying the irCARS response under intense  
689 inflammatory condition. We also documented significant correlations between ferritin, d-  
690 dimer, and Hb and IL-6, illustrating the complex relationship between CRS severity, anemia,  
691 and coagulopathy. Furthermore, an increase in IL-1 family cytokines (IL-1 $\beta$ , IL-18, IL-1RA)  
692 during ICI therapy suggests inflammasome activation, particularly NLRP3, indicating its  
693 substantial influence on the CRS and CARS continuum. NLRP3 inflammasome was reported  
694 for its role in processing and releasing pro-inflammatory cytokines, and its significant  
695 influence on the inflammatory continuum of CRS and CARS (26).

696 The dominant Th1 response associated with ICI, characterized by significant IFN- $\gamma$   
697 production without substantial involvement of IFN- $\alpha$  or Th17 pathways, suggests a specific  
698 immune activation pathway critical for the therapeutic efficacy of ICI. This is further  
699 supported by the elevated levels of IL-10, IL1-RA, CXCL9 and CXCL10 in cluster 1 with  
700 improved OS highlighting these markers as potential biomarkers of enhanced anti-tumor  
701 activity in ICI therapy. Specifically, these inflammatory chemokines bind to the CXCR3  
702 receptor and specifically target activated T lymphocytes and natural killer (NK) cells (39-41).  
703 A pronounced increase in HGF levels and in IL-10/HGF correlation in patients with severe  
704 irAEs (grade 3 and 4) suggests its role as a biomarker for irCARS and for clinical severity.  
705 The correlation between HGF levels and irCARS amplification highlights HGF's potential in  
706 moderating inflammatory responses, possibly aiding in tissue repair and inflammatory  
707 damage mitigation (42). This observation opens avenues for exploring HGF's role in both  
708 irCRS and irCARS, particularly in the context of ICI therapy.

709 Our findings underscore the importance of multi-biomarker strategies in refining survival  
710 predictions and tailoring therapeutic interventions for irCRS. Notably, we observed  
711 contrasting immune patterns between irHLH clusters. Cluster 3, associated with high acute  
712 mortality due to irHLH rather than cancer progression, showed elevated inflammatory  
713 cytokines (IL-6, IL-8, CXCL8, CXCL13, IL1-RA, HGF, SCF) compared to clusters 1 and 2,  
714 which showed better OS and higher levels of CXCL9, CXCL10, IFN- $\gamma$ , and IL-10. This  
715 indicates a broader inflammatory response in irHLH and suggests that robust irCARS  
716 activation could counterbalance intense inflammation. The distinction between the cytokine  
717 profiles in these clusters underscores the complexity of irAEs in irHLH and suggests that  
718 more regulated inflammatory responses in clusters 1 and 2 may lead to improved outcomes.  
719 Elevated pro-inflammatory cytokines in cluster 3 suggest a cytokine milieu contributing to  
720 the severity of irHLH that is distinct from clusters focused on oncologic responses. This

721 analysis highlights the need for tailored therapeutic strategies based on cluster-specific  
722 cytokine patterns and underscores the critical nature of managing the extensive organ  
723 involvement and systemic impact seen in severe irHLH cases. Our comprehensive analysis  
724 highlights the importance of personalized therapeutic approaches to mitigate adverse  
725 outcomes in severe immune-mediated diseases, which is essential to optimize ICI therapy  
726 management, especially in patients with severe irAEs such as irHLH.

727

728 The rationale of our study is based on the observed dichotomy between the Lee criteria for  
729 CRS grading and the HScore in assessing CRS severity and HLH characteristics. We found  
730 significant discrepancies between these criteria, noting cases of high-grade irCRS by Lee  
731 criteria with unexpectedly low HScore, and vice versa. This highlights the complexity of  
732 categorizing irCRS and irHLH and suggests a continuum between them, ranging from purely  
733 biological to mixed clinical manifestations. Our analysis suggests that the HScore alone may  
734 inaccurately represent irCRS G3 and irHLH, leading to potential mismanagement based on  
735 its sensitivity of approximately 71%. These findings underscore that a high HScore doesn't  
736 always warrant aggressive interventions, such as high-dose steroids, typically prompted by  
737 high Lee grades. Cases in which a lower HScore is associated with severe CRS challenge the  
738 stand-alone utility of the HScore to guide immunosuppressive therapy. Our goal was to  
739 identify markers that are more predictive of clinical severity and appropriate initiation of  
740 therapy. This approach acknowledges the insights of the HScore, but argues against its sole  
741 use for critical decisions, advocating a holistic interpretation that considers the broader  
742 clinical context and patient phenotypes. Integrating the Lee criteria and HScore with new  
743 biomarkers may lead to more personalized, effective treatment strategies for irCRS and  
744 irHLH, using both scores and a comprehensive assessment of clinical and inflammatory  
745 markers to improve diagnostic accuracy and interventional guidance.

746 In evaluating 45 biomarkers, our study identified HGF and ferritin as particularly predictive  
747 of irHLH versus irCRS G3, with 100% sensitivity and specificity. Biomarkers associated  
748 with severe irCRS (grade 4) showed strong discriminatory power such as SCF, IL-6, IL-1RA,  
749 CCL2, CXCL9, CXCL13, ASAT, fibrinogen, D-dimer, and prothrombin ratio, while others  
750 such as lymphocyte count and hemoglobin were less effective. In particular, CXCL9 stood  
751 out for its dual role in distinguishing irHLH from irCRS and predicting the need for treatment  
752 intensification with TCZ, underscores the potential for tailored therapeutic strategies.  
753 Similarly, HGF, SCF, IL-1RA and others proved valuable in predicting clinical needs such as  
754 fluid resuscitation, improving patient management and guiding novel treatments. Similarly,  
755 HGF, SCF, IL-1RA, CCL2, IL-18, ferritin, prothrombin ratio, and D-dimer showed dual  
756 performance in predicting hemodynamic instability requiring fluid resuscitation and in  
757 distinguishing irHLH from irCRS. The potential of these biomarkers to predict critical  
758 clinical outcomes, such as hemodynamic instability further underscores their utility in clinical  
759 practice.

760

761 Recent studies are consistent with our findings and showed distinct cytokine profiles in  
762 irHLH compared to sepsis, with increased levels of CXCL9, CXCL10, and CXCL11 in HLH  
763 versus sepsis, while IL-6 was relatively higher in SIRS/sepsis compared to HLH, and IL-10  
764 showed no significant difference(43). In addition, we noted a distinct cytokine signature in  
765 irHLH, significantly differing from sepsis with elevated IL-10, IL-18, IFN- $\gamma$ , CCL2, CCL3,  
766 HGF, SCF, and IL1-RA, along with ferritin and d-dimer. IL-2R did not distinguish between  
767 irHLH and sepsis. Dual inflammatory and biological signatures differentiated the irHLH,  
768 sepsis, and grade 3 CRS groups. IL-10, HGH, IL-18, IL1-RA, and SCF were key in irHLH,  
769 while leukocytes, IL-7, EGF, PDGF-BB, and GM-CSF were prominent in sepsis. Our data  
770 suggest that ferritin, IL-10, EGF and total leukocytes can discriminate between irHLH,



771 irCRS-3 and sepsis. These biomarkers achieved 100% accuracy in our data, highlighting the  
772 potential of these biomarkers in clinical practice for early diagnosis, patient stratification and  
773 tailored therapies.

774

775 Recent studies have shown that T cell activation profiles can discriminate between  
776 hyperinflammatory disorders such as HLH and sepsis, with >7% CD38<sup>high</sup>/HLA-DR+ among  
777 CD8+ T cells being a key discriminator (44). This was extended to CD38<sup>high</sup>/HLA-  
778 DR+CD8+ T cells expressing CD4 (CD4<sup>dim</sup>CD8+ T cells), which correlated with HLH  
779 severity and levels of CXCL9 and IL-18 (45). Our research explores these immunologic  
780 profiles and reveals increased CD38+/HLA-DR+ cell frequencies across multiple T cell  
781 subtypes, indicating a specific and robust immune memory response in irCRS, possibly due  
782 to prior antigen exposure or the nature of the immune stimulus. This distinct T-cell profile  
783 may differentiate irCRS from sepsis and measure the severity of the immune response in  
784 patients undergoing ICI therapy.

785 In addition, we found that neutrophils and monocytes in irCRS patients exhibited more  
786 CD38, CD11c, and CD62L upregulation than in sepsis, suggesting a different activation  
787 profile that could help differentiate irCRS from sepsis. This indicates a different  
788 inflammatory and immunoregulatory environment in irCRS, highlighting the potentially  
789 unique role of innate immune cells in its pathogenesis. The specific activation of monocytes,  
790 which are critical for antigen presentation and cytokine production, highlights their  
791 importance in the severity of irCRS and as possible targets for therapeutic intervention or  
792 disease monitoring markers.

793

794 The significant expansion of our patient cohort from three cases in our previous report (15) to  
795 the inclusion of twelve patients in this study underscores the growing body of evidence

796 supporting the efficacy of TCZ in the treatment of CS-refractory high-grade irCRS. This  
797 larger patient cohort not only reaffirms but also strengthens our confidence in the important  
798 therapeutic potential of TCZ.

799 This study has several limitations, including a small cohort size and a limited number of  
800 paired samples, which may affect the generalizability of the findings. As a single-center  
801 study, it may be subject to selection bias and heterogeneity due to the patient population,  
802 differences in disease stage, prior treatments, and comorbidities. This limitation underscores  
803 the importance of building larger cohorts to address these confounding factors more  
804 accurately. These factors could influence the results of the study. In addition, the lack of  
805 validation in independent cohorts limits the reproducibility and robustness of our conclusions.  
806 Longitudinal data collection from baseline and during ICI treatment could improve data  
807 quality and reliability.

808

809 Despite these limitations, our findings advocate a paradigm shift in the diagnostic approach to  
810 immune-related adverse events and propose a multi-biomarker strategy that not only  
811 improves diagnostic accuracy but also aids in the prognosis and management of irCRS and  
812 irHLH and their distinction from sepsis. This approach promises a significant step toward  
813 personalized medicine. It will enable clinicians to predict treatment response and tailor  
814 interventions with unprecedented accuracy. Ultimately, this research provides the foundation  
815 for a new era in managing irCRS and irHLH characterized by increased diagnostic accuracy,  
816 improved patient outcomes, and personalized therapeutic interventions.

817

## 818 **Acknowledgements**

819 This work was supported by the strategic plan of the CHUV. We would like to express our  
820 gratitude to all the patients who generously contributed their time and samples for this

821 project. We would like to thank Pr Gérard Waeber and Pr Peter Vollenweider for their help in  
822 the clinical care of our patients. We would like to thank Federica Martina for her initial  
823 version of the code used in the article. Visual abstract was created with BioRender.com.

#### 824 **Author contributions**

825 M.O. and D.D. had full access to all data in the study and take responsibility for its integrity  
826 and accuracy. MO conceived, designed the study and drafted the manuscript. D.D., G.P., and  
827 M.O. analyzed and interpreted the data. D.D., A.S., and M.O. collected the data. S.L., N.M.,  
828 H.B., R.D., K.A., N.F., J.D., G.S., L.M., V.M., D.B., A.S., C.S., K.S. and S.P. participated in  
829 the clinical treatments. V.J., R.B. and AN analyzed the CyTOF data. D.D. and M.O. prepared  
830 the figures. J.T. and Y.W. participated in scientific discussion. The manuscript was reviewed  
831 and approved by all authors before submission.

832

#### 833 **Competing interests**

834 MO received honoraria and speaker fees from Moderna, Roche and BMS.

835

836

837


838


839

## 840 Reference

- 841 1. J. Haanen *et al.*, Management of toxicities from immunotherapy: ESMO Clinical Practice  
842 Guideline for diagnosis, treatment and follow-up. *Ann Oncol* **33**, 1217-1238 (2022).
- 843 2. F. Martins *et al.*, Adverse effects of immune-checkpoint inhibitors: epidemiology, management  
844 and surveillance. *Nat Rev Clin Oncol*, (2019).
- 845 3. F. Martins *et al.*, New therapeutic perspectives to manage refractory immune checkpoint-  
846 related toxicities. *Lancet Oncol* **20**, e54-e64 (2019).
- 847 4. A. Ceschi, R. Nosedà, K. Palin, K. Verhamme, Immune Checkpoint Inhibitor-Related Cytokine  
848 Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. *Front Pharmacol*  
849 **11**, 557 (2020).
- 850 5. R. J. Brentjens *et al.*, CD19-targeted T cells rapidly induce molecular remissions in adults with  
851 chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* **5**, 177ra138 (2013).
- 852 6. M. L. Davila *et al.*, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell  
853 acute lymphoblastic leukemia. *Sci Transl Med* **6**, 224ra225 (2014).
- 854 7. U. Winkler *et al.*, Cytokine-release syndrome in patients with B-cell chronic lymphocytic  
855 leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody  
856 (rituximab, IDEC-C2B8). *Blood* **94**, 2217-2224 (1999).
- 857 8. C. L. Freeman *et al.*, Cytokine release in patients with CLL treated with obinutuzumab and  
858 possible relationship with infusion-related reactions. *Blood* **126**, 2646-2649 (2015).
- 859 9. M. Cosenza, S. Sacchi, S. Pozzi, Cytokine Release Syndrome Associated with T-Cell-Based  
860 Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and  
861 Treatment. *Int J Mol Sci* **22**, (2021).
- 862 10. Y. Kogure, Y. Ishii, M. Oki, Cytokine Release Syndrome with Pseudoprogression in a Patient  
863 with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. *J Thorac Oncol* **14**,  
864 e55-e57 (2019).
- 865 11. E. E. Rassy, T. Assi, J. Rizkallah, J. Kattan, Diffuse edema suggestive of cytokine release  
866 syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. *Immunotherapy*  
867 **9**, 309-311 (2017).
- 868 12. S. H. Tay *et al.*, Cytokine Release Syndrome in Cancer Patients Receiving Immune  
869 Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. *Front*  
870 *Immunol* **13**, 807050 (2022).
- 871 13. A. Shimabukuro-Vornhagen *et al.*, Cytokine release syndrome. *J Immunother Cancer* **6**, 56  
872 (2018).
- 873 14. K. Bachmuller *et al.*, Haemophagocytic lymphohistiocytosis in adult critical care. *J Intensive*  
874 *Care Soc* **21**, 256-268 (2020).
- 875 15. B. C. Ozdemir *et al.*, Cytokine-directed therapy with tocilizumab for immune checkpoint  
876 inhibitor-related hemophagocytic lymphohistiocytosis. *Ann Oncol* **31**, 1775-1778 (2020).
- 877 16. P. Rajapakse, H. Andanamala, Hemophagocytic Lymphohistiocytosis Secondary to Immune  
878 Checkpoint Inhibitor Therapy. *World J Oncol* **13**, 49-52 (2022).
- 879 17. M. Sadaat, S. Jang, Hemophagocytic lymphohistiocytosis with immunotherapy: brief review  
880 and case report. *J Immunother Cancer* **6**, 49 (2018).
- 881 18. D. A. Lichtenstein *et al.*, Characterization of HLH-like manifestations as a CRS variant in  
882 patients receiving CD22 CAR T cells. *Blood* **138**, 2469-2484 (2021).
- 883 19. D. T. Teachey *et al.*, Cytokine release syndrome after blinatumomab treatment related to  
884 abnormal macrophage activation and ameliorated with cytokine-directed therapy. *Blood* **121**,  
885 5154-5157 (2013).
- 886 20. R. D. Sandler *et al.*, Diagnosis and Management of Secondary HLH/MAS Following HSCT  
887 and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within  
888 EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and  
889 Transplant Complications Working Party (TCWP). *Front Immunol* **11**, 524 (2020).
- 890 21. E. Karakike, E. J. Giamarellos-Bourboulis, Macrophage Activation-Like Syndrome: A Distinct  
891 Entity Leading to Early Death in Sepsis. *Front Immunol* **10**, 55 (2019).
- 892 22. J. T. van Dissel, P. van Langevelde, R. G. Westendorp, K. Kwappenberg, M. Frolich, Anti-  
893 inflammatory cytokine profile and mortality in febrile patients. *Lancet* **351**, 950-953 (1998).
- 894 23. C. A. Gogos, E. Drosou, H. P. Bassaris, A. Skoutelis, Pro- versus anti-inflammatory cytokine  
895 profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. *J*  
896 *Infect Dis* **181**, 176-180 (2000).

- 897 24. D. Andaluz-Ojeda *et al.*, A combined score of pro- and anti-inflammatory interleukins  
898 improves mortality prediction in severe sepsis. *Cytokine* **57**, 332-336 (2012).
- 899 25. J. A. Kellum *et al.*, Understanding the inflammatory cytokine response in pneumonia and  
900 sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. *Arch*  
901 *Intern Med* **167**, 1655-1663 (2007).
- 902 26. M. Sessler *et al.*, NLRP3 Inflammasome Regulates Development of Systemic Inflammatory  
903 Response and Compensatory Anti-Inflammatory Response Syndromes in Mice With Acute  
904 Pancreatitis. *Gastroenterology* **158**, 253-269 e214 (2020).
- 905 27. S. S. Neelapu *et al.*, Chimeric antigen receptor T-cell therapy - assessment and management  
906 of toxicities. *Nat Rev Clin Oncol* **15**, 47-62 (2018).
- 907 28. D. Porter, N. Frey, P. A. Wood, Y. Weng, S. A. Grupp, Grading of cytokine release syndrome  
908 associated with the CAR T cell therapy tisagenlecleucel. *J Hematol Oncol* **11**, 35 (2018).
- 909 29. J. H. Park *et al.*, Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic  
910 Leukemia. *N Engl J Med* **378**, 449-459 (2018).
- 911 30. N. C. Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0  
912 (2017).
- 913 31. L. Fardet *et al.*, Development and validation of the HScore, a score for the diagnosis of  
914 reactive hemophagocytic syndrome. *Arthritis Rheumatol* **66**, 2613-2620 (2014).
- 915 32. R. C. Bone *et al.*, Definitions for sepsis and organ failure and guidelines for the use of  
916 innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee.  
917 American College of Chest Physicians/Society of Critical Care Medicine. *Chest* **101**, 1644-  
918 1655 (1992).
- 919 33. M. M. Levy *et al.*, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions  
920 Conference. *Crit Care Med* **31**, 1250-1256 (2003).
- 921 34. D. W. Lee *et al.*, Current concepts in the diagnosis and management of cytokine release  
922 syndrome. *Blood* **124**, 188-195 (2014).
- 923 35. J. I. Henter *et al.*, HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic  
924 lymphohistiocytosis. *Pediatr Blood Cancer* **48**, 124-131 (2007).
- 925 36. C. Knaak *et al.*, Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic  
926 reliability of HLH-2004 criteria and HScore. *Crit Care* **24**, 244 (2020).
- 927 37. A. Noto *et al.*, The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-  
928 specific B cell response in viremic infection. *Front Immunol* **13**, 960120 (2022).
- 929 38. A. Noto *et al.*, CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the  
930 Magnitude and the Quality of SARS-CoV-2 Humoral Responses. *Viruses* **14**, (2022).
- 931 39. M. T. Chow *et al.*, Intratumoral Activity of the CXCR3 Chemokine System Is Required for the  
932 Efficacy of Anti-PD-1 Therapy. *Immunity* **50**, 1498-1512 e1495 (2019).
- 933 40. W. Feng *et al.*, Activation of the chemokine receptor 3 pathway leads to a better response to  
934 immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. *Cancer Cell Int*  
935 **22**, 186 (2022).
- 936 41. N. Karin, CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells,  
937 and Beyond. *Front Immunol* **11**, 976 (2020).
- 938 42. M. Perreau *et al.*, The cytokines HGF and CXCL13 predict the severity and the mortality in  
939 COVID-19 patients. *Nat Commun* **12**, 4888 (2021).
- 940 43. H. Lin *et al.*, IFN-gamma signature in the plasma proteome distinguishes pediatric  
941 hemophagocytic lymphohistiocytosis from sepsis and SIRS. *Blood Adv* **5**, 3457-3467 (2021).
- 942 44. V. Chaturvedi *et al.*, T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis  
943 and early sepsis. *Blood* **137**, 2337-2346 (2021).
- 944 45. A. De Matteis *et al.*, Expansion of CD4dimCD8+ T cells characterizes macrophage activation  
945 syndrome and other secondary HLH. *Blood* **140**, 262-273 (2022).

**Fig. 1**



**Fig. 2**

**Fig. 3**



**Fig. 4****A**

	Hscore	True Diagnosis	Probability of HLH (Hscore)	Ferritin	HGF	Tocilizumab
<b>Predicted irCRS G3</b>						
	52	irCRS G3	0.08	1131	255	No
	82	irCRS G3	0.49	66	170	Yes
	94	irCRS G3	1.03	1535	33	Yes
	138	irCRS G3	13.76	1123	203	Yes
	146	irCRS G3	20.74	5523	119	No
<b>HScore cutoff for 100% sensitivity in our cohort</b>						
	<b>154</b>		<b>30.02</b>			
<b>Predicted irHLH</b>						
	162	irHLH	41.26	25861	2000	No
	165	irCRS G3	45.80	4940	188	No
	175	irHLH	60.93	37714	4194	Yes
	208	irCRS G3	91.60	3573	55	Yes
	218	irHLH	94.88	83786	598	Yes
	226	irHLH	96.45	213600	26600	Yes
	230	irHLH	97.00	306630	1255	Yes
	287	irHLH	98.95	705920	1134	Yes

**B****C****D**

Biomarker	irHLH vs irCRS-G3 Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	Cutoff	ROC AUC	ROC P value	%	95% CI	%	95% CI			
Ferritin	< 15692	1	0.0027	100	64.57% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
HGF	< 426.5	1	0.0027	100	64.57% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
SCF	< 13.00	0.9881	0.0034	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
CCL4	< 158.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
IL-10	< 6.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
IL-18	< 169.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
aPTT	< 32.50	0.9714	0.0074	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100
IL-1RA	< 12251	0.9524	0.0066	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
CCL2	< 97.50	0.9286	0.0101	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
D-Dimer	< 12708	0.9143	0.0185	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100
PDGF-B	< 25.50	0.9048	0.0152	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
Prothrombin Ratio	> 65.00	0.9048	0.0152	100	64.57% to 100.0%	66.67	30.00% to 94.08%	84.62	100.00	77.78
ASAT	< 297.5	0.881	0.0223	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CCL11	< 25.50	0.881	0.0223	71.43	35.89% to 94.92%	100	60.97% to 100.0%	84.62	75.00	100.00
CXCL9	< 357.5	0.881	0.0223	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
LIF	< 6.500	0.881	0.0223	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
Fibrinogen	> 1.450	0.8571	0.0321	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
CCL3	< 8.50	0.8452	0.0383	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CXCL10	< 209.5	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CXCL13	< 357.0	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
IFN $\gamma$	< 16.50	0.8333	0.0455	57.14	25.05% to 84.18%	100	60.97% to 100.0%	76.92	66.67	100.00
IL-6	< 42.65	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
Platelets	> 79.00	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
<b>Hscore</b>	<b>&lt; 154.0</b>	<b>0.9286</b>	<b>0.0101</b>	<b>71.43</b>	<b>35.89% to 94.92%</b>	<b>100</b>	<b>60.97% to 100.0%</b>	<b>84.62</b>	<b>75.00</b>	<b>100.00</b>

**E**

Biomarker	Tocilizumab Escalation Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	Cutoff	ROC AUC	ROC P value	%	95% CI	%	95% CI			
CXCL9	< 80.00	0.8889	0.0308	75	30.06% to 98.72%	100	70.09% to 100.0%	92.31	90.00	100.00
Total Bilirubine	< 11.00	0.9167	0.0206	100	51.01% to 100.0%	77.78	45.26% to 96.05%	84.62	100.00	66.67
<b>Hscore</b>	<b>&lt; 170.0</b>	<b>0.75</b>	<b>0.1649</b>	<b>100</b>	<b>51.01% to 100.0%</b>	<b>66.67</b>	<b>35.42% to 87.94%</b>	<b>76.92</b>	<b>100.00</b>	<b>57.14</b>



**Fig. 5**


**A**

Biomarker	Sepsis vs irCRS-G3 & irHLH Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI			
Total Leucocytes	0.9808	0.0046	> 8.900	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
Neutrophils	0.9744	0.0128	> 5.925	100	43.85% to 100.0%	92.31	66.69% to 99.61%	93.75	75.00	100
IL-7	0.9615	0.0066	> 4.000	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
EGF	0.9423	0.0092	> 62.50	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
Fibrinogen	0.9423	0.0092	> 5.850	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
CXCL10	0.9327	0.0108	< 75.00	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
GM-CSF	0.9038	0.0174	> 19.00	100	51.01% to 100.0%	76.92	49.74% to 91.82%	82.35	57.14	100
Alkaline Phosphatase	0.8974	0.037	> 261.5	100	43.85% to 100.0%	69.23	42.37% to 87.32%	75.00	42.86	90
Gamma-GT	0.8974	0.037	> 250.0	100	43.85% to 100.0%	76.92	49.74% to 91.82%	81.25	50.00	100
ALAT	0.8654	0.0315	< 97.00	100	51.01% to 100.0%	76.92	49.74% to 91.82%	82.35	57.14	100
IL-6	0.8462	0.0415	> 203.0	100	51.01% to 100.0%	84.62	57.77% to 97.27%	88.24	66.67	100


**B**

Biomarker	Sepsis vs irCRS-G3 Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI			
Total Leucocytes	1	0.0082	> 8.250	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
Neutrophils	1	0.0167	> 5.925	100	43.85% to 100.0%	100	64.57% to 100.0%	100	100	100
IL-6	1	0.0082	> 203.0	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
EGF	1	0.0082	> 53.50	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
Alkaline Phosphatase	0.9524	0.0304	> 249.0	100	43.85% to 100.0%	85.71	48.69% to 99.27%	90	75	100
IL-7	0.9286	0.0233	> 3.000	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
GM-CSF	0.9286	0.0233	> 19.00	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
Fibrinogen	0.8929	0.0376	> 5.600	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
IL-15	0.8929	0.0376	> 5.500	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
CXCL10	0.875	0.0472	< 75.00	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100




**Fig. 6**

# Supplementary Figure 1






# Supplementary Fig. 3




# Supplementary Fig. 4


**A**




**B**




**C**




**D**




**E**



**F**



**G**



Cluster eG1 vs eG2: HR=2.31 [0.47-11.52], p=0.4164  
 Cluster eG1 vs eG3: HR=12.18 [0.22-665.7], p=0.2207  
 Cluster eG1 vs eG4: HR=6.46 [1.06-39.23], p=0.051  
 Cluster eG2 vs eG3: HR=4.95 [1.05-23.28], p=0.0427  
 Cluster eG2 vs eG4: HR=3.44 [0.64-18.62], p=0.0332  
 Cluster eG3 vs eG4: HR=41.34 [4.44-384.6], p=0.011

# Supplementary Fig. 5

**A**

ID	Diagnosis	HScore	Probability of irHLH	Respiratory Distress	Fluid Resuscitation	Vasopressors	Fresh Frozen Plasma	Immunosuppressive treatments				
								Corticosteroids		Tocilizumab		Number of TRT
								HDS	Highest Dose	TCZ	Dose	
1	irHLH	162	41.4	Yes	Yes	Yes	No	Yes	2 mg/kg	No		0
2	irHLH	175	61.3	Yes	Yes	Yes	Yes	Yes	2 mg/kg	Yes	8 mg/kg	1
3	irHLH	218	95.8	No	No	No	Yes	Yes	1 mg/kg	Yes	8 mg/kg	1
4	irHLH	226	97.4	Yes	Yes	Yes	Yes	Yes	10 mg/kg	Yes	8 mg/kg	1
5	irHLH	230	98.0	Yes	Yes	No	Yes	Yes	10 mg/kg	Yes	8 mg/kg	1
6	irHLH	287	99.9	Yes	Yes	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
7	irCRS Grade 3	138	13.8	No	No	No	No	Yes	5 mg/kg	Yes	8 mg/kg	2
8	irCRS Grade 3	208	92.5	No	No	No	Yes	Yes	N/A	Yes	8 mg/kg	1
9	irCRS Grade 3	94	1.0	Yes	No	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
10	irCRS Grade 3	165	46.0	Yes	No	No	No	No	No	No	No	0
11	irCRS Grade 3	82	0.5	No	No	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
12	irCRS Grade 3	52	0.1	No	No	No	No	Yes	1 mg/kg	No	No	0
13	irCRS Grade 3	146	20.8	No	No	No	No	No	No	No	No	0
<b>n (%) in irHLH</b>				<b>5/6 (83%)</b>	<b>5/6 (83%)</b>	<b>3/6 (50%)</b>	<b>4/6 (67%)</b>	<b>6/6 (100%)</b>			<b>5/6 (83%)</b>	
<b>n (%) in iCRS</b>				<b>2/7 (29%)</b>	<b>0/6 (0%)</b>	<b>0/6 (0%)</b>	<b>1/6 (17%)</b>	<b>5/7 (71%)</b>			<b>4/7 (29%)</b>	

**B**


Biomarker	Fluid Resuscitation Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI			
HGF	1	0.0034	< 866.0	100	67.56% to 100.0%	100	56.55% to 100.0%	100.00	100.00	100.00
SCF	1	0.0034	< 18.50	100	67.56% to 100.0%	100	56.55% to 100.0%	100.00	100.00	100.00
aPTT	1	0.0066	< 43.00	100	67.56% to 100.0%	100	51.01% to 100.0%	100.00	100.00	100.00
Prothrombin Ratio	0.975	0.0054	> 85.00	100	67.56% to 100.0%	80	37.55% to 98.97%	92.31	100.00	88.89
CXCL13	0.95	0.0084	< 357.0	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
Ferritin	0.95	0.0084	< 15692	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
IL-1RA	0.925	0.0128	< 18130	100	67.56% to 100.0%	80	37.55% to 98.97%	92.31	100.00	88.89
PDGF-B	0.925	0.0128	< 29.50	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
D-Dimers	0.9143	0.0185	< 12708	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100.00
CCL4	0.9	0.0192	< 158.0	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
IL-10	0.875	0.0281	< 6.000	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
AST	0.875	0.0281	< 373.5	87.5	52.91% to 99.36%	80	37.55% to 98.97%	84.62	80.00	87.50
IL-18	0.85	0.0404	< 169.0	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
CCL2	0.85	0.0404	< 97.50	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
<b>Hscore</b>	<b>0.875</b>	<b>0.0281</b>	<b>&lt; 154.0</b>	<b>62.5</b>	<b>30.57% to 86.32%</b>	<b>100</b>	<b>56.55% to 100.0%</b>	<b>76.92</b>	<b>62.50</b>	<b>100.00</b>

**C**


Biomarker	Respiratory Distress Predictors			Sensitivity		Specificity		Accuracy	PPV	NPV
	Cutoff	ROC AUC	ROC P value	%	95% CI	%	95% CI			
aPTT	< 35.00	0.9667	0.0106	100	56.55% to 100.0%	83.33	43.65% to 99.15%	90.91	100.00	83.33
Platelets	> 191.5	0.9429	0.0118	80	37.55% to 98.97%	100	64.57% to 100.0%	91.67	87.50	100.00
Prothrombin Ratio	> 82.50	0.9429	0.0118	80	37.55% to 98.97%	100	64.57% to 100.0%	91.67	87.50	100.00
D-Dimer	< 12708	0.9429	0.0118	100	56.55% to 100.0%	85.71	48.69% to 99.27%	91.67	100.00	83.33
CCL2	< 97.50	0.9286	0.0149	100	56.55% to 100.0%	85.71	48.69% to 99.27%	91.67	100.00	83.33
Ferritin	< 15692	0.9143	0.0185	100	56.55% to 100.0%	71.43	35.89% to 94.92%	83.33	100.00	71.43
CRP	< 82.00	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
Hemoglobin	> 98.50	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
IL-18	< 93.00	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
<b>Hscore</b>	<b>&lt; 154.0</b>	<b>0.8286</b>	<b>0.0618</b>	<b>80</b>	<b>37.55% to 98.97%</b>	<b>85.71</b>	<b>48.69% to 99.27%</b>	<b>83.33</b>	<b>85.71</b>	<b>80.00</b>



# Supplementary Fig. 6




# Supplementary Fig. 7




# Supplementary Fig. 8


**A**



**B**




**C**



**D**


**Averaged Gini Coefficient across 100 forests**




**E**

Biomarker	% as main node of trees
Ferritin	75%
HGF	10%
EGF	8%
Leukocytes count	4%
PDGF-B	3%


## Whole Blood



## T cells (from CD3+)




## CD38+ HLA-DR+ in T cells




# Supplementary Figure 9 (continued): Gating strategy from whole blood


B cells+  
NK cells  
(from CD3-)



Monocytes/ DCs  
(from myeloid cells)



Neutrophils  
(from granulocytes)



# Supplementary Figure 9 (continued): list of metal-conjugated antibodies

106Cd	CCR6
111Cd	CD141
112Cd	CD69
113In	CD8
115In	CD4
116Cd	IgA2
141Pr	CD45
142Nd	CD19
143Nd	ICOS
144Nd	IgG3
145Nd	CD31
146Nd	IgD
147Sm	CD7
148Nd	IgA1
149Sm	CD127
150Nd	IgG1
151Eu	CD123
152Sm	CD21
153Eu	CD62L
154Sm	CD3
155Gd	CD27
156Gd	TCR $\gamma\delta$
158Gd	CD10
159Tb	CCR7
160Gd	CD14
161Dy	CD1c
162Dy	CD11c
163Dy	CXCR3
164Dy	CXCR5
165Ho	CD45RO
166Er	CD24
167Er	CD38
168Er	CD66b
169Tm	CD25
170Er	CD45RA
171Yb	CD20
172Yb	IgM
173Yb	TCR $\alpha\beta$
174Yb	HLADR
175Lu	PD1
176Yb	CD56
191Ir	DNA1
193Ir	DNA2
194Pt	CCR4
198Pt	IgG2
209Bi	CD16

# Supplementary Table 1

Cohort description		n = 35	% within cohort
<u>Age</u>		Median (range)	57 (60)
<u>Sex</u>		Male	23 66%
		Female	12 34%
<u>Median times (days)</u>		Median time of onset	58
		Median time of follow up	896
<u>Tumor type</u>		Melanoma	17 49%
		Lung	11 31%
		Urological	3 9%
		Others	4 11%
<u>irAE type</u>		irCRS	28 80%
		among irCRS : irHLH	9 32% of CRS
<u>Sepsis during ICI</u>		Sepsis during ICI	7 20%
<u>irCRS Clinical grade</u>			
Low grade [43%]	1	2	7%
	2	10	36%
High grade [57%]	3	8	29%
	4	8	29%
<u>Immune Checkpoint Inhibitors (ICI)</u>			
anti PD-L1	Atezolimumab	2	6%
	Durvalumab	1	3%
anti PD-1	Pembrolizumab	8	23%
	Nivolumab	3	9%
anti PD-1 + anti CTLA-4	Ipilimumab + Nivolumab	21	60%
<u>ICI per Toxicity (% of grade)</u>			
Grade 1	Ipilimumab + Nivolumab	2	100%
	Grade 2	Ipilimumab + Nivolumab	7 70%
		Pembrolizumab	2 20%
		Durvalumab	1 10%
Grade 3	Ipilimumab + Nivolumab	7	88%
	Pembrolizumab	1	13%
Grade 4	Ipilimumab + Nivolumab	5	63%
	Pembrolizumab	2	25%
	Nivolumab	1	13%
Sepsis during ICI	Pembrolizumab	3	43%
	Nivolumab	2	29%
	Atezolimumab	2	29%
<u>Immunosuppressive treatment (IS) for irCRS</u>			
		Corticosteroids (CS)	3 11%
		CS + anti-IL6R (Tocilizumab)	13 46%
		None	12 43%

## Supplementary Table 2

Patients Receiving Tocilizumab	n (N=12)	%
<u>Sex</u>		
Male	6	50
Female	6	50
<u>Age</u>		
Median (Mean)	46 (48)	
<u>Mortality related to irCRS</u>		
7 days	0	0.00
30 days	0	0.00
<u>Clinical Grading</u>		
irCRS Grade 3	5	41.67
irCRS Grade 4	7	58.33
<u>irHLH</u>		
irHLH within Grade 3	1	20.00
irHLH within Grade 4	7	100.00
<u>Severity factors</u>		
Acute respiratory failure	5	41.67
Acute Kidney Injury	7	58.33
Acute Liver failure	2	16.67
Admission in Intensive or Intermediate Care	5	41.67
DIC	6	50.00
Fluid resuscitation	5	41.67
Vasopressors	2	16.67
High dose of steroids (HDS)	12	100.00
<u>Mortality related to irHLH</u>		
7 days	0	0.00
30 days	0	0.00
<u>irHLH response</u>		
Complete Resolution	12	100.00
<u>Oncological response 3 months after TCZ</u>		
Complete Response (CR)	3	25.00
Stable Disease (SD)	2	16.67
Partial Response (PR)	0	0.00
Progressive Disease (PD)	6	50.00
Not Assessed	1	8.33
<u>Oncological response 6 months after TCZ</u>		
Complete Response (CR)	4	33.33
Stable Disease (SD)	2	16.67
Partial Response (PR)	0	0.00
Progressive Disease (PD)	3	25.00
Not Assessed	3	25.00



# Supplementary Table 4

## Hscore + CRP: HR and P values

Clusters	HR	95% CI of ratio	P value	Significance
Cluster D1 vs Cluster D2	2.642	0.2940 to 23.75	0.3072	ns
Cluster D1 vs Cluster D3	1.419	0.3232 to 6.232	0.6429	ns
Cluster D1 vs Cluster D4	1.603	0.2137 to 12.02	0.6332	ns
Cluster D2 vs Cluster D3	4.788	1.153 to 19.89	0.0323	*
Cluster D2 vs Cluster D4	4.693	0.3573 to 61.65	0.085	ns
Cluster D3 vs Cluster D4	1.319	0.2346 to 7.419	0.7325	ns

## Hscore + CRP + Creatinin: HR and P values

Clusters	HR	95% CI of ratio	P value	Significance
Cluster F1 vs Cluster F2	9.442	0.2762 to 322.7	0.002	**
Cluster F1 vs Cluster F3	9.535	0.2201 to 413.1	0.0004	***
Cluster F1 vs Cluster F4	3.068	0.3150 to 29.87	0.2072	ns
Cluster F2 vs Cluster F3	3.35	0.7693 to 14.59	0.0767	ns
Cluster F2 vs Cluster F4	4.496	0.3293 to 61.38	0.068	ns
Cluster F3 vs Cluster F4	1.504	0.2440 to 9.267	0.6224	ns

## Supplementary Table 5

Cluster 1  
(n=7)      Cluster 2  
(n=18)      Cluster 3  
(n=3)

### Grading irCRS/irHLH

1	0	2	0
2	0	9	0
3	4	4	0
4	3	2	3
... irHLH Patients	4	2	3

### Cancer type

Breast	0	1	0
Digestive	0	2	0
Lung	0	7	2
Melanoma	7	8	0
Genitourinary	0	0	1

### Treatment

TCZ + GC	6	5	2
GC	1	1	1
No Immunosuppressors	0	11	0

# Supplementary Table 6

irHLH vs irCRS-G3 & Sepsis Predictors				Sensitivity		Specificity		Accuracy	PPV	NPV
Biomarker	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI			
Ferritin	1	0.0009	< 23221	100	74.12% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
CCL4	0.9848	0.0013	< 164.0	90.91	62.26% to 99.53%	100	60.97% to 100.0%	94.12	85.71	100.00
HGF	0.9848	0.0013	< 592.5	90.91	62.26% to 99.53%	100	60.97% to 100.0%	94.12	85.71	100.00
IL-1RA	0.9697	0.0018	< 12251	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
IL-10	0.9697	0.0018	< 25.00	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
IL-18	0.9697	0.0018	< 391.0	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
SCF	0.947	0.003	< 21.00	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
aPTT	0.93	0.0085	< 43.85	100	72.25% to 100.0%	80	37.55% to 98.97%	93.33	100.00	90.91
CCL2	0.9242	0.0049	< 211.5	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
D-Dimers	0.92	0.0101	< 12708	80	49.02% to 96.45%	100	56.55% to 100.0%	86.67	71.43	100.00
Fibrinogen	0.9091	0.0067	> 1.450	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
CXCL9	0.9091	0.0067	< 357.5	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
Prothrombin Ratio	0.8939	0.009	> 65.00	100	74.12% to 100.0%	66.67	30.00% to 94.08%	88.24	100.00	84.62
CXCL10	0.8939	0.009	< 196.5	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
CCL3	0.8712	0.0138	< 8.500	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
IFN- $\gamma$	0.8636	0.0159	< 16.50	63.64	35.38% to 84.83%	100	60.97% to 100.0%	76.47	60.00	100.00
Platelets	0.8485	0.0208	> 79.00	81.82	52.30% to 96.77%	83.33	43.65% to 99.15%	82.35	71.43	90.00
CXCL13	0.8333	0.027	< 440.0	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
CCL11	0.803	0.0444	< 25.50	63.64	35.38% to 84.83%	100	60.97% to 100.0%	76.47	60.00	100.00